Skip to main content

In Brief This Week: GATC Biotech; NorDiag; Amoy Diagnostics, AstraZeneca; MGRC Berhad; New York Academy of Sciences

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GATC Biotech will open in early January a new sequencing laboratory in the Life Science Center Dusseldorf in Germany. The new lab will serve scientists in Northern Germany and adjacent countries and provide them with access to the firm's overnight sequencing service.

NorDiag this week said that its third-quarter revenues declined around 10 percent to NOK25.1 million ($4.2 million) from NOK27.9 million year over year. Sales for its sample preparation segment increased to NOK7.5 million from NOK5.4 million. Sales for its HLA typing segment declined to NOK17.5 million from NOK22.6 million, due primarily to a divestment.

Amoy Diagnostics and AstraZeneca are collaborating on workshops in China to demonstrate the use of Amoy's ADx-ARMS technology in detecting epidermal growth factor receptor (EGFR) mutations in tissue from non-small cell lung cancer samples. AstraZeneca sells the EGFR inhibitor Iressa. Amoy noted that it anticipates regulatory approval in China soon to sell its technology for detecting EGFR mutations.

The Malaysian Genomics Resource Centre Berhad said this week that it has commenced two major genome sequencing and analysis projects: the MyGenome project, which is the first multi-ethnic human genome study of the Malaysian population using deep sequencing, and the Proboscis Monkey Genome Project.

The New York Academy of Sciences this week launched the Life Science Angel Network, which is designed to "fill the gap between New York and tri-state area technology transfer offices, entrepreneurs, and venture capitalists by providing capital through member contributions and sponsorships from organizations involved in supporting innovation and building companies."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.